Jolanta Marucha

Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3‐year follow‐up

A Szymanska, Agnieszka Jurecka, Zbigniew Żuber et al. · Acta Paediatrica · 2011 · 69 citations

Efficacy of recombinant human α‐<scp>L</scp>‐iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients

Anna Tylki‐Szymańska, Jolanta Marucha, Agnieszka Jurecka et al. · Journal of Inherited Metabolic Disease · 2010 · 58 citations

Improvement in the range of joint motion in seven patients with mucopolysaccharidosis type II during experimental gene expression‐targeted isoflavone therapy (GET IT)

Jolanta Marucha, Anna Tylki‐Szymańska, Joanna Jakóbkiewicz‐Banecka et al. · American Journal of Medical Genetics Part A · 2011 · 49 citations · Full text

Anthropometric data of 14 patients with mucopolysaccharidosis I: Retrospective analysis and efficacy of recombinant human α-l-iduronidase (laronidase)

Anna Tylki‐Szymańska, Agnieszka Różdżyńska‐Świątkowska, Agnieszka Jurecka et al. · Molecular Genetics and Metabolism · 2009 · 35 citations

Immunodeficiencies, Anthropometric Data, Recombinant Human α-L-iduronidase +6

Rapid deterioration of a patient with mucopolysaccharidosis type I during interruption of enzyme replacement therapy

Grzegorz Węgrzyn, Anna Tylki‐Szymańska, Anna Liberek et al. · American Journal of Medical Genetics Part A · 2007 · 27 citations

Mucopolysaccharidosis Type, Rapid Deterioration, Enzyme Replacement Therapy +2